Tags: Clinical Trials
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
announcements
May 10, 2019
$7.1 Million in New Funding Illustrates the ADDF’s Strong Support of a Diverse Pipeline
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
blog
January 14, 2019
Top 5 Advances in 2018
In 2018 we have seen increased investments in Alzheimer's biomarkers and increased interest in prevention.
announcements
January 11, 2019
New Funding Focuses on Prevention
The Alzheimer's Drug Discovery Foundation awarded new funding to studies that focus on prevention.
announcements
January 9, 2019
New Generation of Therapeutics Based on Understanding of Aging Biology Show Promise for Alzheimer’s
A review by the ADDF published in Neurology® explores novel approaches beyond the common amyloid that could slow or prevent Alzheimer's.
blog
September 24, 2018
Two Decades of Research: The ADDF’s 19th International Conference on Alzheimer’s Drug Discovery
Researchers shared updates on their approaches to developing Alzheimer's treatments at our annual conference.
announcements
September 17, 2018
Dr. Michela Gallagher Wins Alzheimer’s Drug Discovery Foundation’s Prestigious Goodes Prize
Michele Gallagher, PhD, is the recipient of the fourth Melvin R. Goodes Prize, which includes a $150,000 award to support the therapeutic development of AGB-101.
announcements
September 13, 2018
$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments
The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.
announcements
July 13, 2018
New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction
The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.
announcements
May 10, 2018
$2.5 Million in New Funding Exemplifies ADDF’s Strategy
We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease.
blog
May 4, 2018
Alzheimer’s Clinical Trials, Explained
Learn about clinical trials, an important and growing part of our funding at the Alzheimer’s Drug Discovery Foundation.
blog
March 14, 2018
ADDF Grantees Headline NIH Alzheimer’s Summit
ADDF-supported research was at the forefront of the Summit and the National Plan to Address Alzheimer's.
blog
January 30, 2018
Meeting the Challenge of CTE
For CTE Awareness Day, we highlight our support of diagnostic tools and treatments for this disease.
announcements
January 8, 2018
$1.8 Million in New Funding Supports Clinical Stage Treatments
The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.
blog
January 2, 2018
Top Five Alzheimer’s Advances in 2017
Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.
blog
November 28, 2017
Closing in on a Cure: Dr. Roberta Diaz Brinton and Allopregnanolone
With funding from the ADDF since 2004, Dr. Roberta Diaz Brinton has developed what may become the first ever regenerative treatment for Alzheimer's disease.
announcements
November 14, 2017
Three New Grants Keep Promising Programs Forging Ahead
The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.
announcements
November 1, 2017
New Report Highlights Innovation in Alzheimer’s Clinical Trials
Closing in on a Cure: 2017 Alzheimer’s Clinical Trials Report surveys the 126 drugs in clinical development for Alzheimer’s disease—20% of which received support from the Alzheimer’s Drug Discovery Foundation.
blog
October 30, 2017
CTAD Conference Highlights Our Funded Research
Wednesday marked the beginning of National Alzheimer's Disease Awareness Month and the 10th Clinical Trials on Alzheimer's Disease conference, which featured a record amount of research we supported.
announcements
September 14, 2017
Dr. Roberta Diaz Brinton Wins Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize
Dr. Brinton has pioneered a promising neurogenesis therapy for Alzheimer’s disease.
announcements
September 13, 2017
18th Annual Conference on Alzheimer’s Drug Discovery Showcases Non-Amyloid Research
Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.
blog
September 5, 2017
Driving Innovation in Alzheimer’s Therapies
At our 18th Annual Conference on Alzheimer’s Drug Discovery in Jersey City, the impact of our approach will take center stage.
blog
August 17, 2017
Inflammation, The Driver of Alzheimer’s Disease?
A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's.
announcements
July 11, 2017
Latest Funding Includes Support for Innovative Clinical Trial
The ADDF announces four new grants, including support for an innovative clinical trial, two novel drug programs, and a biomarker for CTE.
announcements
June 29, 2017
2016 Annual Report Released
The 2016 Annual Report, titled “From Idea to Impact,” highlights the enormous progress the ADDF has made toward finding effective treatments for Alzheimer’s disease.
blog
May 16, 2017
Clinical Trials Inspiring Hope
Since 1998, the ADDF has invested over $100 million in the best ideas to cure Alzheimer's. We are seeing the impact of our efforts, with many promising drugs in clinical trials on the way.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).